TOKYO -- Takeda Pharmaceutical's state-of-the-art research and development center in the waterfront city of Shonan has yet to yield a blockbuster treatment since its founding a decade ago -- a weak track record the Japanese drugmaker is determined to improve.
"The Shonan base has made a significant contribution to neuroscience," said Takashi Ichikawa, who heads the company's neuroscience research unit, on a conference call explaining Takeda's R&D efforts. "Shonan's pharmaceutical science level is recognized globally," he said.
.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
